Drugs / GEC255
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05768321 | Nov 2021 → Feb 2024 | cancer | GenEros Biopharma Hangzhou Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEC255 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05768321 ↗ |
| Route | Oral | “daily oral dosing with GEC255 tablets” NCT05768321 ↗ |